taurine has been researched along with Chemical Dependence in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medications for the treatment of substance use disorders are effective yet underutilized." | 2.50 | Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. ( Friedmann, PD; Park, TW, 2014) |
| "Schizophrenia is noted for the remarkably high prevalence of substance use disorders (SUDs) including nicotine (>85%), alcohol and stimulants." | 2.43 | Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. ( Coyle, JT, 2006) |
| "They also responded to questions about substance use, criminal, and sexual behavior which were used to define a latent HRB variable." | 1.72 | Personality Disorders, Risky Behaviors, and Adversity: The Moderating Role of Resilience. ( Conner, BT; Flynn, TP; Parnes, JE, 2022) |
| "The use of medications to treat substance use disorders (SUDs) has emerged as a potentially central part of the treatment armamentarium." | 1.37 | Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. ( Abraham, AJ; Knudsen, HK; Roman, PM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flynn, TP | 1 |
| Parnes, JE | 1 |
| Conner, BT | 1 |
| Curran, CP | 1 |
| Marczinski, CA | 1 |
| Münzer, T | 1 |
| Klemperer, EM | 1 |
| Hughes, JR | 1 |
| Naud, S | 1 |
| Park, TW | 1 |
| Friedmann, PD | 1 |
| Petit, A | 1 |
| Karila, L | 1 |
| Lejoyeux, M | 1 |
| Reif, S | 1 |
| Horgan, CM | 1 |
| Hodgkin, D | 1 |
| Matteucci, AM | 1 |
| Creedon, TB | 1 |
| Stewart, MT | 1 |
| Thirthalli, J | 1 |
| Chand, PK | 1 |
| Capone, C | 1 |
| Kahler, CW | 1 |
| Swift, RM | 1 |
| O'Malley, SS | 1 |
| Alam, DA | 1 |
| Martorana, A | 1 |
| Roman, PM | 1 |
| Abraham, AJ | 1 |
| Knudsen, HK | 1 |
| Clark, DB | 1 |
| O'Brien, CP | 1 |
| Doran, CM | 1 |
| Duszynski, KM | 1 |
| Beilby, JJ | 1 |
| Mattick, RP | 1 |
| Coyle, JT | 1 |
| Green, AI | 2 |
| Drake, RE | 1 |
| Brunette, MF | 2 |
| Noordsy, DL | 2 |
| O'Keefe, C | 1 |
| Soyka, M | 1 |
| Kranzler, HR | 1 |
| Berglund, M | 1 |
| Gorelick, D | 1 |
| Hesselbrock, V | 1 |
| Johnson, BA | 1 |
| Möller, HJ | 1 |
| Schuckit, MA | 1 |
| Wickelgren, I | 1 |
| Litten, RZ | 1 |
| Allen, JP | 1 |
| Yarborough, WH | 1 |
| Iwata, H | 1 |
| Matsuda, T | 1 |
| Yamagami, S | 1 |
| Hirata, Y | 1 |
| Baba, A | 1 |
| Grant, KA | 1 |
| Woolverton, WL | 1 |
13 reviews available for taurine and Chemical Dependence
| Article | Year |
|---|---|
Taurine, caffeine, and energy drinks: Reviewing the risks to the adolescent brain.
Topics: Adolescent; Brain; Caffeine; Central Nervous System Stimulants; Energy Drinks; Humans; Risk Factors; | 2017 |
[Doping with illegal and legal substances in old age].
Topics: Adult; Aged; Aged, 80 and over; Aging; Amino Acids; Creatine; Doping in Sports; Female; Humans; Illi | 2018 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomiz | 2018 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfira | 2014 |
[Abuse of energy drinks: does it pose a risk?].
Topics: Adult; Caffeine; Energy Drinks; Glucuronates; Humans; Mental Disorders; Performance-Enhancing Substa | 2015 |
The implications of medication development in the treatment of substance use disorders in developing countries.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Comorbidity; Developing Countries; Disul | 2009 |
Addiction treatment: level of care determination.
Topics: Acamprosate; Alcohol Deterrents; Behavior Therapy; Cognitive Behavioral Therapy; Health Status Indic | 2011 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Na | 2003 |
Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Animals; Antipsychotic Agents; Clozapine; Diagnostic Imaging; Gluta | 2006 |
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Hum | 2008 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Di | 2008 |
Recent developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Anti-Anxiety Agents; Buspirone; Disulfiram; Ethanol; Female; Humans | 1996 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl | 1999 |
1 trial available for taurine and Chemical Dependence
| Article | Year |
|---|---|
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Fema | 2011 |
11 other studies available for taurine and Chemical Dependence
| Article | Year |
|---|---|
Personality Disorders, Risky Behaviors, and Adversity: The Moderating Role of Resilience.
Topics: Adolescent; Adverse Childhood Experiences; Humans; Personality Disorders; Resilience, Psychological; | 2022 |
Access to Addiction Pharmacotherapy in Private Health Plans.
Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Serv | 2016 |
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists | 2011 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorde | 2012 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Femal | 2006 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (P | 2007 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcoholism; Female; Humans; Male; Substance-Related Disorders; Taurine | 1996 |
Teaching the brain to take drugs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-R | 1998 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; | 2001 |
Changes of taurine content in the brain tissue of barbiturate-dependent rats.
Topics: Animals; Aspartic Acid; Barbiturates; Brain Chemistry; gamma-Aminobutyric Acid; Glutamates; Humans; | 1978 |
Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals.
Topics: Acamprosate; Animals; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Self Administr | 1989 |